Platform Partnerships Scenic Biotech's Cell-Seq discovery platform underpins a robust neurometabolic and neurodegenerative target space and already powers collaborations with Genentech, BMS, Alnylam and Ono. This positions Scenic as a source of novel targets and target-validation capabilities for pharma partners, offering discovery-stage collaboration, target prioritization, and possibly licensing access to the platform and resulting programs.

CNS Asset Potential The company is pursuing brain-penetrant small-molecule inhibitors aimed at elevating endogenous BMP levels to restore lysosomal function, signaling CNS-focused programs ripe for co-development, lead optimization, or licensing deals with pharma partners seeking next-generation CNS therapeutics.

Oligo Capabilities Scenic's collaboration with Secarna to develop disease-modifying oligonucleotide therapies demonstrates competence in antisense and oligonucleotide modalities. This creates cross-sell opportunities for pharma clients seeking integrated target discovery and oligo development services, as well as potential co-development arrangements.

Strategic Growth With notable funding and a recent leadership appointment, Scenic is positioned to scale its pipeline and actively pursue partnerships. Based in Amsterdam, the company can engage EU-based and global pharma, offering early discovery access, platform-based collaborations, and milestone-driven deals.

Credibility Boost A Nature publication and progress in a first-in-class program underscore the company's credibility and trend toward modifier therapies for CNS and neurometabolic diseases. This strengthens the case for partnering on novel targets such as ABHD18 and PLA2G15, with opportunities across discovery, translational work, and clinical-stage collaboration.